PubMed Health⌕ Search

PubMed · 1809452

Respiratory muscle function in asthma.

Abstract

Asthma increases the load on the ventilatory pump by causing simultaneous increases in airway resistance, lung volume, and minute ventilation. The inspiratory muscles bear the majority of this load, whereas expiratory muscle recruitment is relatively minor. Respiratory muscle strength and endurance appear to be normal in stable asthmatics. During acute attacks, airway closure and expiratory airflow limitation result in a dynamic increase in end-expiratory lung volume. In turn, hyperinflation compromises the function of inspiratory muscles, especially that of the diaphragm, by reducing their force-generating capacity (muscle shortening) and impairing their mechanical advantage on the chest wall. Thus, exacerbations of asthma cause an acute increase in mechanical load together with decreased ventilatory capacity, thereby predisposing to inspiratory muscle fatigue and precipitating hypercapnic respiratory failure in severe cases. Management of ventilatory failure in asthma consists of mechanical unloading of the inspiratory muscles by positive pressure ventilation together with pharmacotherapy (anti-inflammatory and bronchodilating agents) to improve airway function. The strategy of mechanical ventilation is aimed at minimizing dynamic hyperinflation, which increases inspiratory muscle load as well as promotes barotrauma.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A R Hill. 1991. Respiratory muscle function in asthma.. https://pubmed.ncbi.nlm.nih.gov/1809452/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗